BioSpace News Archive

Promethera® Biosciences S.A., global innovator in cell-based medicines and liver diseases, and Hao Tian Development Group Limited a diversified investment holding company, through its subsidiary Aceso Life Science Holding Limited, announced that the companies have entered into an agreement to form a joint venture.

Lannett Company, Inc. and Cediprof, Inc., a part of the Neolpharma Pharmaceutical Group family of companies, said that the companies have entered into an interim exclusive supply and distribution agreement for Cediprof’s FDA approved Levothyroxine Sodium Tablets USP.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced that the company will host a conference call and live webcast on Thursday, July 30, 2020 at 8:00 a.m.

Todos Medical Ltd. announced that its partner supplier 3D Medicines Corporation has received authorization from the Brazilian Health Surveillance Agency to distribute its COVID-19 qPCR test kits and ANDis extraction systems.

IRADIMED CORPORATION announced that the Company will release its 2020 second quarter financial results before the market opens on Thursday, July 30th.

Abiomed, Inc. announced that on Thursday, August 6, 2020, the Company will release financial results for the first quarter of fiscal 2021.

AnchorDx, a leading biotechnology company developing novel NGS-based early cancer detection and disease monitoring tests, announced that it has entered into a multi-year collaboration with the Lung Cancer Initiative at Johnson & Johnson1, to conduct a lung cancer study.

Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, announced that Jodie P. Morrison has assumed the chair role of its board of directors, effective July 15, 2020.

Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today announced the appointment of Jennifer K. Simpson, Ph.D., as President and Chief Executive Officer. Dr. Simpson was also appointed to the Company’s Board of Directors. Dr. Simpson brings more than two decades of public company executive and fundraising experience in oncology dr

Highlights: International study will be conducted in a laboratory at a leading academic institution in the U.S. to evaluate anti-viral activity of RECCE ® 327 and new antiviral formulation RECCE ® 529 Expanded program utilizing Centers for Disease Control (CDC) SARS-CoV-2 clinical isolate SARS-Related Coronavirus 2, Isolate USA-WA1/2020 Preliminary data anticipated September 2020 SYDNEY, Australia, July 16, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Compa